Allodynic Therapeutics, Inc. is pioneering the development of a naltrexone-acetaminophen combination aimed at addressing acute migraine and co-occurring anxiety. This clinical-stage pharmaceutical company has successfully completed four investigator-initiated clinical trials, demonstrating the potential effectiveness of this combination in treating various pain conditions, particularly neuropathic pain, which affects millions of Americans. The naltrexone-acetaminophen combination is protected by multiple U.S. patents, extending its market exclusivity until 2037. The research indicates that both components are effective individually, but their combination may provide enhanced relief, particularly in emotional pain, suggesting a synergistic effect.

The mechanism of action for the naltrexone-acetaminophen combination involves targeting multiple biological pathways. Naltrexone is believed to reduce pain by blocking the Toll-Like Receptor 4 (TLR4), which is associated with the production of pro-inflammatory cytokines that contribute to neuropathic pain. Meanwhile, acetaminophen is thought to inhibit cyclooxygenase-2 (COX-2), leading to reduced levels of prostaglandin E2 (PGE-2). This dual-action approach not only addresses acute migraine symptoms but also holds promise in combating the opioid crisis by providing an alternative to opioid prescriptions, which carry significant risks of addiction and limited effectiveness.

United States

Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037. 

Allodynic Therapeutics

Company Details